Comparing In-hospital Mortality With Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate
Comparing In-hospital Mortality With Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate
Life-Threatening Bleeding in the Anticoagulated Patient: Real World Evidence
Life-Threatening Bleeding in the Anticoagulated Patient: Real World Evidence
Andexanet Alfa Is Associated With Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients With Factor Xa Inhibitor–Related Major Bleeding
Andexanet Alfa Is Associated With Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients With Factor Xa Inhibitor–Related Major Bleeding
Case Presentation: Management of a Patient With Vitamin K Antagonist-Associated Intracranial Hemorrhage (ICH)
Case Presentation: Management of a Patient With Vitamin K Antagonist-Associated Intracranial Hemorrhage (ICH)
Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence
Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence
Case Presentation: Management of a Patient With Factor Xa-Associated ICH Using Specific Reversal Therapy
Case Presentation: Management of a Patient With Factor Xa-Associated ICH Using Specific Reversal Therapy
Development of a Care Pathway Using Specific Reversal Agents for Anticoagulated Patients With ICH
Development of a Care Pathway Using Specific Reversal Agents for Anticoagulated Patients With ICH
Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH
Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH
Repletion Management for Vitamin K Antagonist Anticoagulation
Repletion Management for Vitamin K Antagonist Anticoagulation
Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding
Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding
Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing
Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing
Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience
Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience
Hematoma Expansion and Clinical Outcomes Comparison in ICH: Clinical Trial Results Versus Real World Care
Hematoma Expansion and Clinical Outcomes Comparison in ICH: Clinical Trial Results Versus Real World Care